MedTrace Logo

Treating Paroxysmal Nocturnal Haemoglobinuria Patients With rVA576

NCT03588026 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2025-04-09

No results posted yet for this study

Summary

rVA576 for patients with Paroxysmal Nocturnal Hemoglobinuria (PNH).

Conditions

  • Paroxysmal Nocturnal Hemoglobinuria (PNH)

Interventions

DRUG

rVA576

6 months of treatment, rVA576 plus SOC. Followed by a further 3 months of rVA576 plus SOC. In total, 9 months on rVA576 plus SOC.

OTHER

Standard of care (SOC)

6 months on SOC followed by 3 months of treatment with rVA576 plus SOC. In total, 3 months on rVA576 plus SOC.

Sponsors & Collaborators

  • AKARI Therapeutics

    lead INDUSTRY

Principal Investigators

  • Andrius Degulys, MBBS · Vilnius University Hospital Santaros Klinikos

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-07
Primary Completion
2020-09-03
Completion
2020-09-03

Countries

  • Kazakhstan
  • Lithuania
  • Sri Lanka

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03588026 on ClinicalTrials.gov